Breaking the one antibody-one target axiom

Area of Science:

• Biochemistry
• Immunology
• Organic Chemistry

Background:

• Chemically programmed antibodies (cpAbs) integrate small-molecule drug design with immunotherapy.
• Traditional immunochemistry follows a "one antibody-one target" rule, limiting therapeutic strategies.
• Aldolase catalytic antibodies, like mAb 38C2, are key components in developing novel antibody-based therapeutics.

Purpose of the Study:

• To develop a novel proadapter assembly strategy for creating chemically programmed antibodies (cpAbs).
• To investigate the efficacy of cpAbs in targeting and treating integrin alpha(v)beta 3-expressing breast cancer.
• To evaluate the therapeutic potential of cpAbs in preclinical models of breast cancer metastasis.

Main Methods:

• Utilized antibody 38C2-catalyzed transformation to unveil a reactive tag for stable covalent antibody conjugation.
• Synthesized an integrin alpha(v)beta 3 antagonist with a designed proadapter.
• Studied cpAb efficacy in human breast cancer cell lines (MDA-MB-231, MDA-MB-435) and animal models.

Main Results:

• Demonstrated effective in vitro and in vivo assembly of cpAbs.
• Achieved selective retargeting of cpAbs to integrin alpha(v)beta 3-expressing breast cancer cells.
• Showcased enhanced circulatory half-life, intracellular delivery, and significant therapeutic improvement over peptidomimetics in breast cancer metastasis models.

Conclusions:

• The proadapter assembly strategy enables efficient creation and application of cpAbs.
• cpAbs demonstrate significant potential for targeted cancer therapy, particularly for integrin alpha(v)beta 3-positive breast cancers.
• This technology offers a promising platform for developing advanced immunotherapeutics for disease treatment and diagnosis.